Why is increasing Endogenous Neurosteroids a Better Therapeutics Approach than dosing Exogenous Neurosteroids?

The human brain is a complex network of billions of interconnected cells, organized in many networks communicating with one another. Some CNS disorders arise from dysregulation in the modulation of these networks, either by altered levels of signaling molecules like neurosteroids or the receptors they target. Boosting the brain’s natural [...]

What is the Safety Profile of GRX-917?

Etifoxine (and therefore GRX-917) has an excellent safety/pharmacological profile, based on a safety profile review by ANSM in France (2000-2012) which analyzed over 14 million prescriptions of etifoxine. Non addictive (no cases of abuse, misuse or pharmacodependence) No tolerance, withdrawal or rebound Low ADRs (21 per million) based on +14 [...]

2019-09-22T19:29:11+00:00, |

What’s Wrong with Current Anxiety Medications?

The first-line anxiety medications (SSRIs/SNRIs) take 4-6 weeks to take effect and work in less than 50% of anxiety patients. The second line anxiety medications (benzodiazepines) are highly addictive, have serious side effects and historically have been involved in approximately 1/3 of fatal prescription overdoses in the United States.

2019-09-22T19:29:55+00:00, |

What is GRX-917’s Mechanism of Action?

GRX-917's main mechanism of action increases the amount of naturally occurring neurosteroids (like allopregnanolone) by activation of TSPO on mitochondria. This increase of endogenous neurosteroids occurs in areas in the brain where they are used to activate GABA receptors, slowing dysregulated brain activity in diseases like anxiety and depression, but [...]

What is GRX-917?

GRX-917 is a proprietary (patent-protected until 2036), improved version of Etifoxine, an anxiety drug first approved in France 39 years ago. GRX-917 is a deuterated version of Etifoxine (specific hydrogen atoms were replaced by isotopic deuterium (heavy hydrogen) atoms). Like the vast majority of deuterated drug analogs, GRX-917 retains the [...]